Cellectis - bioresearch

> news & events > press releases

press releases

 

 

PDF
19 Jul 2010
New Study Shows Meganuclease-Driven Targeted Integration Using Cellectis bioresearch’s cGPS® CHO-K1 kit to be highly efficient for drug discovery.
PDF
16 Jun 2010
Cellectis bioresearch Establishes The Genome Customization Award (TGCA)
PDF
08 Jun 2010
Cellectis bioresearch and Lonza Enter Development and Commercial Manufacturing Agreement
PDF
24 Feb 2010
Cellectis bioresearch to present new tools for the production of therapeutic proteins at the 2010 Cell Line Development and Engineering Conference in Prague.
PDF
17 Dec 2009
Cellectis bioresearch launches first kit from cGPS® Custom line for use in human cell lines.
PDF
10 Dec 2009
Cellectis bioresearch and tebu-bio join forces for the distribution of cGPS® and cGPS® Custom targeted integration kits.
PDF
07 Dec 2009
Cellectis bioresearch announces the launch of its first cGPS® kit for use in gene function studies
PDF
04 Nov 2009
Cellectis bioresearch launches cGPS® CHO-S CEMAX® - an efficient protein production kit
PDF
12 Oct 2009
Cellectis Acquires Vectocell® Technology to Accelerate Therapeutic Development Programs
PDF
05 Oct 2009
Latest Launch in Cellectis bioresearch’s cGPS® Product Family Enables Screening Against Difficult-to-Express Drug Targets
PDF
16 Jun 2009
Cellectis bioresearch lance cGPS® Custom, la première gamme de kits au monde permettant l’intégration ciblée d’un gène dans des lignées cellulaires naturelles
PDF
10 Jun 2009
Cellectis bioresearch adds Celonic’s High-Producer CEMAX® Cell Line to Portfolio
PDF
05 May 2009
Laboratoires Servier signs licensing agreement with Cellectis for use of π10® modified cell lines in drug screening
PDF
30 Jan 2009
Cellectis bioresearch appoints Luc Selig as Vice President Sales & Marketing
PDF
01 Dec 2008
Cellectis BioResearch, announces the market launch of a first revolutionary research kit
PDF
30 Jun 2008
Biotechnology company Cellectis S.A. announces the inception of two subsidiaries: Cellectis BioResearch to develop and market research kits and Cellectis Genome Surgery to develop therapeutics.